Traditional Korean Medicine for Non-Small Cell Lung Cancer Patient Undergoing Pembrolizumab Immunotherapy: A Case Report
![]() |
Shim, So-hyun
(Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Seo, Hee-jeong (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) Seo, Hyung-bum (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) Cho, Im-hak (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) Lee, Chan (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) Kim, So-yeon (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) Han, Chang-woo (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) Park, Seong-ha (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) Yun, Young-ju (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) Lee, In (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) Kwon, Jung-nam (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) Hong, Jin-woo (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) Choi, Jun-yong (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) |
1 | Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial. Lancet 2016;387(10027):1540-50. DOI |
2 | Herbst RS, Garon EB, Kim DW, Cho BC, Perez Gracia JL, Han JY, et al. LBA63Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). Annals of Oncology 2018;29(suppl_8). |
3 | Sgambato A, Casaluce F, Gridelli C. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly. Expert opinion on biological therapy 2017;17(5):565-71. DOI |
4 | Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England journal of medicine 2015;372(21):2018-28. DOI |
5 | Lee KW, Kim YS, Son CG, Cho JH, Yoo HS, Lee JH, et al. Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer. Journal of pharmacopuncture 2016;19(3):259-63. DOI |
6 | Wu X, Chung VC, Lu P, Poon SK, Hui EP, Lau AY, et al. Chinese Herbal Medicine for Improving Quality of Life Among Nonsmall Cell Lung Cancer Patients: Overview of Systematic Reviews and Network Meta-Analysis. Medicine 2016;95(1):e2410. DOI |
7 | Seo HG, Jin YJ, Song MH, Kim IT, Park JH, Jung JS, et al. A Case of End-stage non-small cell Lung Cancer Patient with Brain Metastasis Treated with Pembro lizumab with Integrative Medicine Therapy. J of Kor Traditional Oncology 2018;23(2):11-25. DOI |
8 | Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. (November 27, 2017). |
9 | Ryu HS, Lee JY, Oh HK, Yoon SW. A Survey on Korean Medicine Doctors for Cancer Symptoms Care in Korean Medicine Treatments. J of Kor Traditional Oncology 2017;22(1):23-35. DOI |
10 | Ryu HS, Yoon SS, Lee JY, Yoon SW. Perspectives of Cancer Patients on Korean Medicine Treatments: A Cross-sectional Survey. J Int Korean Med 2017;38(3):319-26. DOI |
11 |
Park GY, Bae CH, Park SY, Kim JH, Ko WS, Kim YH. Inhibitory Effect of Dendrobium moniliforme on NO and IL- |
12 | Zhang LL, Wang X. Wang Xisheng Chief Physician's Experience in Treating Lung Cancer. Jounal of Shanxi College of Traditional Chinese Medicine 2010;33(4):29-30. |
13 | Han IS, Kim BW. The Effect of Astragali Radix on Cyclophosphamide-induced Leukocytopenia. Korean J Orientint Med 2006;27(3):579-88. |
14 | Lee SO, Seo JH, Lee JW, Yoo MY, Kwon JW, Choi SU, et al. Inhibitory Effect of the Rhizone Extract of Atractylodes japonica on the proloferation of Human Tumor Cell Lines. Kor J Pharmacogn 2005;36(3):201-4. |
15 | Park JH, Lee JM, Lee CH, Cho JH, Jang JB, Lee KS. Inhibitory Effect of the Rhizone Extract of Atractylodes japonica on the proloferation of Human Tumor Cell Lines. J Korean Obstet Gynecol 2010;23(4):1-9. DOI |
16 | Lee JY, Lee JM, Lee CH, Cho JH, Jang JB, Lee KS. Antitumor and Immunomodulatory Activities of Platycodon grandiflorum. J Korean Obstet Gynecol 2010;23(4):10-9. DOI |
17 | Minchom A, Punwani R, Filshie J, Bhosle J, Nimako K, Myerson J, et al. A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma. Eur J Cancer 2016;61:102-10. DOI |
18 | Park SH, Chi GY, Choi YH, Eom HS. Apoptosis and Autophagy Induction of A549 Human Lung Cancer Cells by Methylene Chloride Extracts of Morus alba L. Korean J Oriental Physiology & Pathology 2010;24(6):942-9. |
19 | Oh MT, Eom HS, Chi GY. Antiproliferative Effect and Apoptotic Mechanism of Extract of Corydalis Yanhusuo on Human Hepatocarcinoma Cells. Korean J Oriental Physiology & Pathology 2007;21(6):1437-49. |
20 | Kasymjanova G, Grossman M, Tran T, Jagoe RT, Cohen V, Pepe C, et al. The potential role for acupuncture in treating symptoms in patients with lung cancer: an observational longitudinal study. Curr Oncol 2013;20(3):152-7. DOI |
21 | EB, WD T. World Cancer Report. Lyon 2014. |
22 | Schwartz AG, Cote ML. Epidemiology of Lung Cancer. Advances in experimental medicine and biology 2016;893:21-41. DOI |
23 | Horn L, Lovly CM, Johnson DH. Neoplasms of the Lung. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 19e. New York, NY: McGraw-Hill Education; 2015. |
24 | Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 2004;13(4):863-8. DOI |
25 | Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 Expression in Lung Cancer. J Thorac Oncol 2016;11(7):964-75. DOI |
26 | Park SY. Analysis of cutaneous adverse events of PD-1 inhibitors, Nivolumab and Pembrolizumab. Dept. of Social and Health Pharmacy Sungkyunkwan University 2017. |
27 | Li TM, Yu YH, Tsai FJ, Cheng CF, Wu YC, Ho TJ, et al. Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan. Journal of ethnopharmacology 2018;213:92-100. DOI |
28 | Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016;60:12-25. DOI |
![]() |